Kazia Therapeutics Limited ADR Dossier
Qualitative Analysis
Business overview
Kazia Therapeutics Limited (NASDAQ: KZIA) is a clinical-stage, oncology-focused biotechnology company headquartered in Sydney, Australia. The company is dedicated to developing innovative, high-impact therapies designed to reprogram tumor biology and address significant unmet medical needs in challenging cancers. Kazia's lead program is paxalisib, an orally administered, brain-penetrant dual inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is being developed to treat glioblastoma, brain metastases, and other central nervous system (CNS) tumors, as well as advanced breast cancers such as triple-negative breast cancer (TNBC). The company's pipeline also includes EVT801, a small-molecule selective inhibitor of VEGFR3 licensed from Evotec SE; NDL2, a first-in-class nuclear PD-L1 degrader; and MSETC, a selective SETDB1-targeted epigenetic drug development platform.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a single-asset focus to a multi-modal platform targeting stable tumor states. This includes integrating paxalisib (transcriptional reprogramming), NDL2 (immune protein degradation), and MSETC (chromatin regulation) under a unified epigenetic strategy.
Expected impact: Aims to overcome treatment resistance in aggressive and immunotherapy-refractory cancers, expanding the addressable market.
Expanding the patient enrollment of the Phase 1b trial evaluating paxalisib in combination with pembrolizumab and standard chemotherapy in advanced triple-negative breast cancer from 12 to 36 patients.
Expected impact: Designed to generate a broader clinical and translational dataset to better assess objective response rate (ORR), progression-free survival (PFS), and biomarkers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of exclusive, worldwide rights to a first-in-class SETDB1-targeted epigenetic platform to target chromatin regulation, drug resistance, and immune evasion.
Financial impact: Upfront license fee of $1,390,000 paid, with future tiered revenue-sharing on commercialization receipts.
Strategic Partnerships
In-licensed the first-in-class NDL2 PD-L1 degrader program, targeting resistant, post-translationally modified forms of the PD-L1 protein to overcome checkpoint inhibitor resistance.
Terms: One-time upfront payment of approximately $1.39 million, with Kazia responsible for all development costs and sharing a percentage of future commercialization revenue.